{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04322955\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["cabozantinib","nivolumab"]],"indication":null,"name":"Cyto-KIK","nct_id":"NCT04322955","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cyto-kik-nct04322955. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Cyto-KIK","arms":[{"description":"All study participants will receive the same study medications, cabozantinib and nivolumab. The study drug, nivolumab, will be administered through an IV infusion every 4 weeks and cabozantinib will be administered orally daily. Initially participants will receive study treatment for 12 weeks. The cabozantinib will then be stopped prior to the nephrectomy. Initially patients enrolled on the study will be assigned to cohort 1.\n\nPatients who are assigned to cohort 1 will be treated with cabozantinib until 21 days prior to surgery. A patient in cohort 1 will be evaluable for assessment of the cabozantinib washout interval (\"evaluable patients\") if they\n\n1. complete at least 10 of the 14 scheduled cabozantinib doses in the two week period prior to stopping cabozantinib AND\n2. have surgical resection of the primary tumor.\n\nIn cohort 2, subjects will receive cabozantinib until 14 days prior to nephrectomy.","label":"Treatment with cabozantinib and nivolumab with nephrectomy","type":"EXPERIMENTAL"}],"collaborators":["Exelixis","Bristol-Myers Squibb"],"completion_date":{"date":"2028-02","type":"ESTIMATED"},"conditions":["Kidney Cancer","Renal Cell Carcinoma"],"enrollment":{"count":38,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cabozantinib","otherNames":["XL184"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["BMS-936558"],"type":"DRUG"},{"name":"Cytoreductive nephrectomy","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-06-05","lead_sponsor":"Mark Stein","official_title":"Cyto-KIK; TRIAL (CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy (Nivolumab) and Targeted Kinase Inhibition (Cabozantinib)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants with a Complete Response","timeFrame":"Up to 5 years after completion of treatment"}],"references":[],"start_date":{"date":"2020-06-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition","url":"https://clinicaltrials.gov/study/NCT04322955"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cyto-kik-nct04322955"}